Citations

Clear

2236 citation(s) found for "Ju, Angela".

Urine Immunoglobulin Light Chain Fragments Detected by MALDI-TOF Mass Spectrometry
Moonen, Danelle, Murray, Elijah J, Willrich, Maria Alice V. , Kohlhagen, Mindy , Murray, David , Moonen, Danelle H, Willrich, Maria A , Kohlhagen, Mindy C, Murray, David L , Dispenzieri, Angela

Mayo Clinic

Clinical Chemistry | July 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/clinchem/hvag085 | PMID 42467676 Get It

Key Performance Indicators for Clinical Pharmacy Practice and Administration in Inpatient/Acute Care Settings: An Opinion of the Clinical Administration Practice and Research Network of the American College of Clinical Pharmacy
Mercado, Angela , Noble, Jacob M. , Irwin, Adriane N. , Badowski, Melissa E. , Bangalore, Nitish , Caliendo, G C, Chan, David C. M. , Dumont, Zachary J. , Groth, Christine M. , Humaideh, Mais Anis, Nguyen, TuTran , Salvatus, Marc , Sullivan, Jesse , Thambi, Mathew , Welch, R , Noble, Jacob , Sullivan, Jesse B , Welch, Ron W , Parrish, Richard H , Dumont, Zack , Caliendo, Gina, Thambi, Mathew , Parrish, Richard H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | July 11, 2026 | Volume: 9 | Issue: 8 | Pages: No page available

10.1002/jac5.70252 | PMID 42432869 Get It

ABSTRACT Key performance indicators (KPIs) are quantifiable measures that describe critical success factors of an organization. Their vital role in ensuring the delivery of quality health care services necessitates the development of KPIs relevant to inpatient clinical pharmacy practice. This opinion paper from the American College of Clinical Pharmacy (ACCP) Clinical Administration Practice and Research Network (CADM PRN) describes the rationale, methodology, and outcomes of a consensus process to identify a focused set of inpatient/acute care clinical pharmacy KPIs. Leveraging a modified Delphi approach, the CADM PRN convened an Expert Panel of clinical pharmacy leader members to build a consensus‐driven set of KPIs reflecting clinical, operational, patient‐centered, and financial contributions of clinical pharmacists in the inpatient/acute care setting. From a previous ACCP White Paper, a total of 15 KPIs were identified across four domains: (1) clinical practice and patient safety, (2) clinical outcomes and readmissions, (3) medication education and patient engagement, and (4) financial and operational value. The CADM PRN posits that the establishment and implementation of standardized KPIs are essential for measuring and demonstrating the value of clinical pharmacy services in modern health care, offers pragmatic, consensus‐based KPIs for evaluating clinical pharmacy services supporting resource justification, and advancing the visibility and impact of pharmacists in acute care practice. As hospitals shift toward value‐based care, robust KPI frameworks will be critical for optimizing patient outcomes, supporting financial sustainability, and justifying appropriate staffing. Future efforts should focus on pilot testing, addressing implementation barriers, and achieving broader acceptance for KPIs across the profession.
Longitudinal Modeling of Pitching Workload and Countermovement Jump Performance as Determinants of Fastball Velocity and Consistency in Collegiate Baseball Pitchers
Burke, Adam A. , Saine, Noelle D., King, Erica L. , Ja, Fields, Miller, Angela D. , Green, Bowling, Jones, Margaret T. , Jones, Margaret T , Fields, Jennifer B., Jagim, Andrew R.

Mayo Clinic

Journal of Strength & Conditioning Research | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1519/jsc.0000000000005602 | PMID 42423608 Get It

Abstract Burke, AA, Saine, ND, King, EL, Fields, JB, Jagim, AR, Miller, AD, Green, BC, and Jones, MT. Longitudinal modeling of pitching workload and countermovement jump performance as determinants of fastball velocity and consistency in collegiate baseball pitchers. J Strength Cond Res XX(X): 000–000, 2026—Maintenance of four-seam fastball (FSFB) velocity across the baseball season is critical, yet the extent to which workload and neuromuscular status relate to velocity is unclear. Thus, aims of the current study were to assess the relationship between external pitching workload metrics and FSFB velocity; quantify within-season FSFB velocity; and examine how countermovement jump (CMJ) performance predicts FSFB velocity. Collegiate pitchers ( n = 8) completed weekly CMJ testing during a 15-week, 53-game season. Countermovement jump metrics included jump height (JH), reactive strength index–modified (RSImod), peak braking force, and peak propulsive force normalized to body mass. Workload variables (innings, total pitches, FSFB pitches) and FSFB velocity were evaluated via repeated measures correlation (RMCORR). A longitudinal heat map visualized velocity trends, and a hierarchical location–scale model assessed predictors of mean velocity and variance. Repeated measures correlation showed weak negative associations between FSFB velocity and innings ( r = −0.15, p = 0.11), total pitches ( r = −0.18, p = 0.05), and FSFB pitches ( r = −0.18, p = 0.05). Heat map analysis identified 3 distinct velocity clusters. Location model results indicated no predictors of mean velocity. The scale model showed JH ( γ = −0.060, p = 0.001) predicted reduced velocity variance, and RSImod ( γ = 3.800, p < 0.001) predicted increased variance. Findings suggest that velocity patterns varied across athletes, where greater workloads were negatively associated with FSFB pitch velocity. Further, CMJ performance related to velocity stability rather than mean velocity. Routine longitudinal monitoring and continued strength-power training are recommended to support FSFB velocity.
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies
Habermann, T. M., Rhee, Frits van, Nishimura, Yoshito , Dispenzieri, Angela , Rhee, Frits van

Mayo Clinic

Expert Opinion on Biological Therapy | July 9, 2026 | Volume: 26 | Issue: 6 | Pages: 605-613

10.1080/14712598.2026.2702010 | PMID 42423097 Get It

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331
Casey, Dana L. , Renfro, Lindsay A., Wu, Yue , McCarten, Kathleen, Pei, Qinglin , Milgrom, Sarah A., Cho, Steve, Keller, Frank G., Punnett, Angela, Kelly, Kara M., Castellino, Sharon M., Hoppe, Bradford S , Casey, Dana L , McCarten, Kathleen M. , Belsky, Jennifer A. , Keller, Frank G. , Punnett, Angela , Hodgson, David , Hoppe, Bradford S. , Kelly, Kara M. , Castellino, Sharon M.

Mayo Clinic

British Journal of Haematology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70625 | PMID 42419755 Get It

Summary Outcomes for high‐risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra‐nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2–21 years with high‐risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE‐PC) versus Bv‐AVEPC. Patients with stage IV disease, determined by protocol‐defined and centrally reviewed Positron Emission Tomography ‐ Computed Tomography (PET‐CT), were identified. Baseline characteristics and progression‐free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE‐PC and 167 (49%) Bv‐AVEPC. PFS was highest with lung‐only involvement (4‐year PFS 88.6%) and lowest with bone marrow‐only involvement (4‐year PFS 71.9%). Compared to ABVE‐PC, Bv‐AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33–0.85) and in the lung‐only and bone‐only subgroups. However, no PFS benefit was observed in those with bone marrow‐only involvement. Among paediatric patients with stage IV cHL, Bv‐AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.
POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management
Dispenzieri, Angela, Dispenzieri, Angela , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70438 | PMID 42411740 Get It

ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnosis The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. Risk Stratification Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. Risk‐Adapted Therapy For those patients with a dominant plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement should receive systemic therapy. Corticosteroids are temporizing, but alkylators and lenalidomide are the mainstays of treatment, the former either in the form of low dose conventional therapy or as high‐dose conditioning for stem cell transplantation. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Daratumumab combinations also appear promising based on case series. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Long‐Term Outcomes After Retropubic and Transobturator Sling Procedures: Reoperation for Recurrent Stress Urinary Incontinence
Trad, Ayssa Teles Abrão , Nashar, Sherif A. El, Madsen, Annetta M., Occhino, John A. , Gebhart, John B. , McGree, Michaela E. , Fought, Angela J. , Trabuco, Emanuel C. , El Nashar, Sherif A, Linder, Brian J , El‐Nashar, Sherif A. , Linder, Brian J. , Madsen, Annetta M.

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/1471-0528.70295 | PMID 42392760 Get It

ABSTRACT Objective To evaluate long‐term failure rates and complications after retropubic and transobturator midurethral sling procedures for primary stress urinary incontinence (SUI). Design Retrospective cohort study. Setting Academic medical centre. Population A previously described cohort of patients ( n = 1881) who underwent midurethral sling procedures (2002–2012) and a covariate‐matched cohort of patients with retropubic ( n = 570) or transobturator ( n = 317) slings. Methods Health record review with follow‐up extended by 9 years (through December 31, 2022). Main Outcome Measures Treatment failure (reoperation for recurrent SUI) and procedure‐associated complications. Results The duration of assessment was extended by 6.9 years for the retropubic group and by 6.4 years for the transobturator group. The median (IQR) follow‐up was 11.1 (5.1–14.5) years (retropubic, 11.4 [5.9–14.6]; transobturator, 9.6 [2.6–13.7]). Higher risk of reoperation was observed with transobturator (8.8%) than retropubic (4.4%) slings (unadjusted hazard ratio [HR], 2.29 [95% CI, 1.49–3.54]; p < 0.001; covariate‐matched analysis HR, 1.91 [95% CI, 1.15–3.17]; p = 0.01). The increased risk of reoperation with a transobturator sling was higher when the procedure was combined with prolapse repair (unadjusted HR, 6.34 [95% CI, 3.09–13.02]; p < 0.001; covariate‐matched analysis HR, 3.96 [95% CI, 1.35–11.58]; p = 0.01). Higher rates of reoperation for urinary retention were observed for the retropubic group than for the transobturator group (covariate‐matched analysis HR, 8.39 [95% CI, 1.11–63.22]; p = 0.04). Conclusion In this long‐term follow‐up study, midurethral slings had a low failure rate. Women with SUI undergoing transobturator sling placement plus prolapse repair had a greater risk of reoperation. However, women with retropubic slings had a greater risk of urinary retention requiring intervention.
Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season
Zambrano, Laura, Newhams, Margaret M., Payne, Amanda B., Orzel-Lockwood, Amber O., Halasa, Natasha B., Calixte, Jemima, Chiotos, Kathleen, Crandall, Hillary , Cameron, Melissa A. , Coates, Bria M. , Michelson, Kelly N., Schuster, Jennifer E., Nofziger, Ryan A. , Chauhan, Jigar C., Maamari, Mia , Kong, Michele, Martine, Lora M., Guzman‐Cottrill, Judith A. , Bhumbra, Samina S. , Irby, Katherine , Staat, Mary Allen, Bradford, Tamara T. , Wellnitz, Kari, Ml, Stockwell, Zinter, Matt, Hymes, Saul, Levy, Emily R. , Biggs, Austin , Lindsey, Katherine, Campbell, Angela P., Simeone, Regina M. , Zambrano, Laura D. , Newhams, Margaret M. , Payne, Amanda B. , Halasa, Natasha , Calixte, Jemima M., Maddux, Aline B. , Chiotos, Kathleen , Kamidani, Satoshi , Zerr, Danielle M. , Gertz, Shira J. , Michelson, Kelly Nicole , Schuster, Jennifer E. , Chauhan, Jigar , Shein, Steven L. , Kong, Michele , Hume, Janet R. , Staat, Mary Allen , Wellnitz, Kari , Zinter, Matt S. , Schwartz, Stephanie P. , Hymes, Saul, Lindsey, Katherine N. , Campbell, Angela P. , Randolph, Adrienne G.

Mayo Clinic

No container title available | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.26.26356705 Get It

Abstract Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children <2 years of age. RSV immunization with infant monoclonal antibody or maternal vaccine is recommended to protect all U.S. infants in their first RSV season. For certain high-risk children aged 8−19 months entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-associated respiratory failure in children during their second season. Objectives To describe children admitted to the pediatric intensive care unit (PICU) for RSV during their second RSV season by preexisting health conditions, and to compare demographic and clinical characteristics across groups. Design, Setting, and Participants Surveillance registry of children 8-<24 months old admitted to the PICU in 30 pediatric hospitals in the 2023-2024/2024-2025 RSV seasons. All children had an RSV-positive respiratory sample and received respiratory support with high flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation (IMV). Exposure Preexisting health conditions potentially increasing risk of severe RSV disease. Main Outcomes and Measures Patients were classified into four mutually exclusive groups by preexisting health conditions: 1) U.S. nirsevimab eligible criteria, 2) other identified RSV risk conditions (with some evidence of increased risk for severe RSV), 3) other preexisting conditions, and 4) no preexisting conditions. Patient demographic characteristics and level of respiratory support received were compared. Results Among 574 children: 47 (8.2%) had U.S. nirsevimab eligibility criteria, 76 (13.2%) had other RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. A higher proportion of children with nirsevimab eligibility factors (40.4%) than those with other identified RSV risk conditions (17.1%) required IMV, which was higher than other (10.4%) or no (5.9%) preexisting health conditions (p trend <0.001). Conclusions and Relevance Approximately 20% of children admitted to the PICU with severe RSV were in the defined groups that met U.S. nirsevimab-eligibility criteria or that had an identified RSV risk condition associated with known risk for severe RSV. A considerable proportion of both groups of children required IMV for respiratory support. These findings may help inform future deliberations regarding U.S. second season nirsevimab-eligibility recommendations. Key Points Question What preexisting health conditions are present in children aged 8–<24 months admitted to the pediatric intensive care unit for severe RSV disease in their second RSV season and how do clinical outcomes differ? Findings Among 574 children, 8% were eligible for nirsevimab in the U.S. and 13% had other preexisting conditions with known risk for severe RSV. Children with preexisting conditions, particularly those eligible for nirsevimab, were more likely to require invasive mechanical ventilation than those without. Meaning These findings may inform future deliberations regarding which children in their second RSV season might benefit from RSV preventive products.
Pollen Season Timing and Concentrations in the United States: Developing a Standardized Pollen Dataset Using Data from the National Allergy Bureau (NAB) (2003–2024)
Manangan, Arie P., Brown, Claudia L., Werner, Angela , Katz, Daniel S. W., Rorie, Andrew, Voelker, Dayne, Gabrish, Pamela, Hess, Jeremy , MPH, Paul J. Schramm, MS, , Manangan, Arie P. , Brown, Claudia , Katz, Daniel S. W. , Rorie, Andrew C. , Voelker, Dayne , Schramm, Paul J.

Mayo Clinic

Atmosphere | June 30, 2026 | Volume: 17 | Issue: 7 | Pages: 635

10.3390/atmos17070635 Get It

Pollen exposure drives allergic disease in millions of Americans, yet no standardized, publicly available national pollen dataset has existed until now. We describe the first nationally standardized and publicly available dataset of pollen season timing and airborne pollen concentrations. The data were derived from the National Allergy Bureau™ (NAB™), the only pollen and mold measuring network in the United States certified by the American Academy of Allergy, Asthma & Immunology (AAAAI), and curated, processed, and disseminated by the U.S. Centers for Disease Control and Prevention (CDC). The 2003–2024 dataset provides standardized measures of (1) taxa-specific historical average main pollen season (MPS) concentrations and timing (e.g., start dates, peak dates, end dates, season length); (2) taxa-specific yearly MPS concentrations and timing; (3) grouped weekly MPS concentrations, levels, and timing; and (4) grouped daily pollen levels and MPS timing. Pollen concentrations are reported as pollen grains per cubic meter (PPCM). MPS timing is computed using a 3-day consecutive method: season start occurs after the first occurrence of three consecutive days with concentrations > 1.0 PPCM; season peak is the day of maximum concentration; and season end occurs after the first occurrence of three consecutive days with concentrations < 1.0 PPCM after the peak. Historical average timing is calculated in a 365-day-of-year format and converted to calendar dates using 2024 as a reference year for display and consistency. By combining long-term data from monitoring sites across the country, this dataset shows how pollen levels vary over time and across geographic locations. This resource supports tracking pollen trends, linking pollen with weather and climate factors, and informing public health action, clinical care, and communication about population exposure and the impact to allergic diseases such as asthma and hay fever.
E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma
Seelisch, Jennifer , Mauz‐Körholz, Christine , Kelly, Kara M, Link, Michael P., Punnett, Angela, Stoevesandt, Dietrich, Kaste, Sue C. , McCarten, Kathleen M. , Kurch, Lars , Mauz-Koerholz, Christine , McCarten, Kathleen , Kurch, Lars , Hoppe, Bradford S , Flerlage, Jamie E , Kelly, Kara M. , Punnett, Angela , Palese, Monica , Hoppe, Bradford S. , Flerlage, Jamie E.

Mayo Clinic

Blood Advances | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026019753 | PMID 42361346 Get It